Clinical Trial Detail

NCT ID NCT02544633
Title Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Mirati Therapeutics Inc.
Indications

non-small cell lung carcinoma

Therapies

Glesatinib

Age Groups: adult

Additional content available in CKB BOOST